In the US, follow-on vaccines can launch from 2029. Shingrix is sold by GSK. GSK's 20-F lists the main US patent to 2029. Sales GBP 3.6B; the US share is falling as fewer unvaccinated adults remain, and two thirds of sales now come from outside the US.
Shingrix's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a vaccine. Vaccines are hard to copy, so competition after patents expire usually arrives slowly.
Who's lined up to copy Shingrix
No US filing found We found no US copy of Shingrix in development. Competition is more likely from rival shingles vaccines in trials.
Patent-expiry estimate. GSK's 20-F lists the main US patent to 2029. Sales GBP 3.6B; the US share is falling as fewer unvaccinated adults remain, and two thirds of sales now come from outside the US.
Shingrix is 11% of GSK's 2025 revenue (≈$4.8B of $43.1B). With Trelegy and Nucala, the drugs tracked here add up to 26% of GSK's revenue losing US exclusivity by 2029. Turnover GBP 32.7B.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Shingrix is highlighted.
Pharma Patent Cliff by readouts.io. "Shingrix patent expiration: US loss of exclusivity 2029." Updated 8 October 2026. https://pharmapatentcliff.com/shingrix
Embed
Free to use on your site with the source link. It shows the latest data whenever the page loads.